Global Lung Cancer Therapeutic Market Research and Analysis, 2015-2021
The Global Lung Cancer Therapeutic Market is expected to grow at the CAGR of 13.2 % during 2016-2021. The Global Lung Cancer Therapeutic Market is growing at a modest rate due to rise in incidence prevalence rate of Lung cancer across the globe. The adoption of lung cancer drugs and innovative lung surgeries are expected to boost the global lung cancer market. Huge demand is created by rising diagnostic centers across the globe. Investment and grants from government and private players are driving the market. Successful clinical trials and FDA approval are the key factors creating huge scope in Global Lung Cancer Therapeutic Market. Adoption of Lung Cancer Therapeutic Market drugs such as Platinol, Taxol, Gemzar, Alimta, Iressa, Xalkori & Tarceva is increasing. Personalized medicines and drug discovery & development has significant contribution in the growth of Lung Cancer Therapeutic Market.
Geographical Insights
North America and Europe has a considerable contribution to the growth of Global Lung Cancer Therapeutic Market followed by APAC region. The key driving forces include rising incidence of lung cancer Diseases and adoption of lung cancer drugs and surgeries across the globe. Emerging economies such as China, India, Japan, and Korea have most lung cancer patients and with improved healthcare system and healthcare spending APAC region looks promising for Global Lung Cancer Therapeutic Market. Improved standard of living, infrastructural development and favorable government policies are some other factors that will boost the APAC market. The report includes detailed Market Overview, Market Determinants, Company Profiling, Sector Analysis, Market Segmentation, Geographical Analysis, Pipeline Analysis, Patent Analysis, Strategic Recommendations, Key Company Analysis, Key Findings, Analyst Insights and predictive analysis of the market.
Competitive Insights
The Global Lung Cancer Therapeutic Market companies include Boehringer Ingelheim, Abbvie, Eli Lilly, F. Hoffmann-La Roche GlaxoSmithKline, Merck Serono and Novartis. Lung Cancer Therapeutic companies are constantly focusing on R&D, partnerships, M&A, innovation and technological advancement.
Market Segmentation
Global Lung Cancer Therapeutic Market Research And Analysis
Comprehensive research methodology of Global Lung Cancer Market.
This report also includes detailed and extensive market overview with historical analysis & key analysts insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the Global Lung Cancer Market.
Insights about market determinants which are stimulating the Global Lung Cancer Market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
Geographical Insights
North America and Europe has a considerable contribution to the growth of Global Lung Cancer Therapeutic Market followed by APAC region. The key driving forces include rising incidence of lung cancer Diseases and adoption of lung cancer drugs and surgeries across the globe. Emerging economies such as China, India, Japan, and Korea have most lung cancer patients and with improved healthcare system and healthcare spending APAC region looks promising for Global Lung Cancer Therapeutic Market. Improved standard of living, infrastructural development and favorable government policies are some other factors that will boost the APAC market. The report includes detailed Market Overview, Market Determinants, Company Profiling, Sector Analysis, Market Segmentation, Geographical Analysis, Pipeline Analysis, Patent Analysis, Strategic Recommendations, Key Company Analysis, Key Findings, Analyst Insights and predictive analysis of the market.
Competitive Insights
The Global Lung Cancer Therapeutic Market companies include Boehringer Ingelheim, Abbvie, Eli Lilly, F. Hoffmann-La Roche GlaxoSmithKline, Merck Serono and Novartis. Lung Cancer Therapeutic companies are constantly focusing on R&D, partnerships, M&A, innovation and technological advancement.
Market Segmentation
Global Lung Cancer Therapeutic Market Research And Analysis
- Platinol
- Taxol
- Gemzar
- Alimta
- Iressa
- Hycamtin
- Gilotrif
- Taxotere
- Xalkori
- Navelbine
- Avastin
- Tarceva
- Others
Comprehensive research methodology of Global Lung Cancer Market.
This report also includes detailed and extensive market overview with historical analysis & key analysts insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the Global Lung Cancer Market.
Insights about market determinants which are stimulating the Global Lung Cancer Market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.4. EXCEPTIONS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. PIPELINE ANALYSIS
2.3. ANALYST INSIGHT
2.3.1. KEY FINDINGS & CURRENT MARKET TRENDS
2.3.2. RECOMMENDATION
2.3.3. CONCLUSION
2.4. REGULATION
2.4.1. UNITED STATES
2.4.2. EUROPEAN UNION
2.4.3. CHINA
2.4.4. INDIA
2.4.5. REST OF THE WORLD
2.5. PIPELINE ANALYSIS
2.5.1. KEYTRUDA MK-3475 NON-SMALL CELL LUNG CANCER DRUG
2.5.2. ATEZOLIZUMAB (ANTI-PDL1, RG7446, MPDL3280A) ROCHE
2.5.3. RG6016 (ROCHE)
2.5.4. TRASTUZUMAB EMTANSINE (T–DM1)
2.5.5. RG7604 PIK3CA
2.5.6. ALECTINIB (RG7853)
2.5.7. OTHERS
2.6. NEWLY APPROVED DRUGS
2.6.1. ALECENSA (ALECTINIB), ROCHE
2.6.2. KEYTRUDA (PEMBROLIZUMAB), MERCK
2.6.3. OPDIVO (NIVOLUMAB), BRISTOL-MYERS SQUIBB
2.6.4. PORTRAZZA (NECITUMUMAB), ELI LILLY
2.6.5. TAGRISSO (OSIMERTINIB), ASTRAZENECA
2.6.6. ABITREXATE (METHOTREXATE)
2.6.7. AVASTIN (BEVACIZUMAB)
2.6.8. DOCETAXEL
2.6.9. FOLEX (METHOTREXATE)
2.6.10. OTHERS
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. RISE IN INCIDENCE & PREVALENCE RATE OF CANCER DISEASES
3.1.2. RISE IN INVESTMENT AND GRANTS FROM GOVERNMENT AND PRIVATE PLAYERS
3.1.3. RISE IN DIAGNOSTIC CENTERS ACROSS THE GLOBE
3.1.4. GROWTH IN PHARMACEUTICAL MARKET OF LUNG CANCER
3.1.5. RESEARCH & DEVELOPMENT IN LUNG CANCER MARKET
3.1.6. ADOPTION OF INNOVATIVE LUNG SURGERY
3.1.7. FDA CLEARANCE TO LUNG CANCER DRUGS
3.1.8. RISE IN ADOPTION OF PERSONALIZED MEDICINES
3.1.9. RISING MORTALITY RATE DUE TO LUNG CANCER
3.2. RESTRAINT
3.2.1. HIGH COST OF GLOBAL LUNG CANCER DRUGS AND SURGERIES
3.2.2. REIMBURSEMENT POLICIES MAY AFFECT THE GROWTH OF THE MARKET
3.3. OPPORTUNITY
3.3.1. UNTAPPED APAC REGION HAVE HUGE OPPORTUNITY FOR GLOBAL LUNG CANCER MARKET
3.3.2. SUCCESSFUL CLINICAL TRIALS AND FDA APPROVALS
MARKET SEGMENTATION
4.1. LUNG CANCER DRUGS MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
4.1.1. PLATINOL
4.1.2. TAXOL
4.1.3. GEMZAR
4.1.4. ALIMTA
4.1.5. IRESSA
4.1.6. HYCAMTIN
4.1.7. GILOTRIF
4.1.8. TAXOTERE
4.1.9. XALKORI
4.1.10. NAVELBINE
4.1.11. AVASTIN
4.1.12. TARCEVA
4.1.13. OTHERS
COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UK
6.2.2. GERMANY
6.2.3. SPAIN
6.2.4. FRANCE
6.2.5. ITALY
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. REST OF ASIA PACIFIC
6.4. REST OF THE WORLD
COMPANY PROFILES
7.1. ABBVIE
7.1.1. INTRODUCTION
7.1.2. ABBVIE PRODUCT PORTFOLIO
7.1.3. ABBVIE RECENT ACTIVITIES
7.2. AGENNIX
7.2.1. INTRODUCTION
7.2.2. AGENNIX PRODUCT PORTFOLIO
7.2.3. AGENNIX RECENT ACTIVITIES
7.3. AMGEN
7.3.1. INTRODUCTION
7.3.2. AMGEN PRODUCT PORTFOLIO
7.3.3. AMGEN RECENT ACTIVITIES
7.4. ASTRAZENECA
7.4.1. INTRODUCTION
7.4.2. ASTRAZENECA PRODUCT PORTFOLIO
7.4.3. ASTRAZENECA RECENT ACTIVITIES
7.5. BOEHRINGER INGELHEIM
7.5.1. INTRODUCTION
7.5.2. BOEHRINGER INGELHEIM PRODUCT PORTFOLIO
7.5.3. BOEHRINGER INGELHEIM RECENT ACTIVITIES
7.6. CELGENE
7.6.1. INTRODUCTION
7.6.2. CELGENE PRODUCT PORTFOLIO
7.6.3. CELGENE RECENT ACTIVITIES
7.7. CELLDEX
7.7.1. INTRODUCTION
7.7.2. CELLDEX PRODUCT PORTFOLIO
7.7.3. CELLDEX RECENT ACTIVITIES
7.8. EISAI
7.8.1. INTRODUCTION
7.8.2. EISAI PRODUCT PORTFOLIO
7.8.3. EISAI RECENT ACTIVITIES
7.9. ELI LILLY
7.9.1. INTRODUCTION
7.9.2. ELI LILLY PRODUCT PORTFOLIO
7.9.3. ELI LILLY RECENT ACTIVITIES
7.10. F. HOFFMANN-LA ROCHE
7.10.1. INTRODUCTION
7.10.2. F. HOFFMANN-LA ROCHE PRODUCT PORTFOLIO
7.10.3. F. HOFFMANN-LA ROCHE RECENT ACTIVITIES
7.11. GLAXOSMITHKLINE
7.11.1. INTRODUCTION
7.11.2. GLAXOSMITHKLINE PRODUCT PORTFOLIO
7.11.3. GLAXOSMITHKLINE RECENT ACTIVITIES
7.12. HELSINN
7.12.1. INTRODUCTION
7.12.2. HELSINN PRODUCT PORTFOLIO
7.12.3. HELSINN RECENT ACTIVITIES
7.13. IMCLONE
7.13.1. INTRODUCTION
7.13.2. IMCLONE PRODUCT PORTFOLIO
7.13.3. IMCLONE RECENT ACTIVITIES
7.14. MERCK SERONO
7.14.1. INTRODUCTION
7.14.2. MERCK SERONO PRODUCT PORTFOLIO
7.14.3. MERCK SERONO RECENT ACTIVITIES
7.15. NOVARTIS
7.15.1. INTRODUCTION
7.15.2. NOVARTIS PRODUCT PORTFOLIO
7.15.3. NOVARTIS RECENT ACTIVITIES
7.16. ONCOGENEX
7.16.1. INTRODUCTION
7.16.2. ONCOGENEX PRODUCT PORTFOLIO
7.16.3. ONCOGENEX RECENT ACTIVITIES
7.17. OSI PHARMACEUTICALS
7.17.1. INTRODUCTION
7.17.2. OSI PHARMACEUTICALS PRODUCT PORTFOLIO
7.17.3. OSI PHARMACEUTICALS RECENT ACTIVITIES
7.18. PEREGRINE
7.18.1. INTRODUCTION
7.18.2. PEREGRINE PRODUCT PORTFOLIO
7.18.3. PEREGRINE RECENT ACTIVITIES
7.19. PFIZER, INC.
7.19.1. INTRODUCTION
7.19.2. PFIZER, INC. PRODUCT PORTFOLIO
7.19.3. PFIZER, INC. RECENT ACTIVITIES
7.20. PIERRE FABRE
7.20.1. INTRODUCTION
7.20.2. PIERRE FABRE PRODUCT PORTFOLIO
7.20.3. PIERRE FABRE RECENT ACTIVITIES
7.21. QIAGEN
7.21.1. INTRODUCTION
7.21.2. QIAGEN PRODUCT PORTFOLIO
7.21.3. QIAGEN RECENT ACTIVITIES
7.22. ROCHE
7.22.1. INTRODUCTION
7.22.2. ROCHE PRODUCT PORTFOLIO
7.22.3. ROCHE RECENT ACTIVITIES
7.23. SANOFI
7.23.1. INTRODUCTION
7.23.2. SANOFI PRODUCT PORTFOLIO
7.23.3. SANOFI RECENT ACTIVITIES
7.24. SYNTA
7.24.1. INTRODUCTION
7.24.2. SYNTA PRODUCT PORTFOLIO
7.24.3. SYNTA RECENT ACTIVITIES
7.25. TELIK
7.25.1. INTRODUCTION
7.25.2. TELIK PRODUCT PORTFOLIO
7.25.3. TELIK RECENT ACTIVITIES
7.26. TEVA PHARMACEUTICAL
7.26.1. INTRODUCTION
7.26.2. TEVA PHARMACEUTICAL PRODUCT PORTFOLIO
7.26.3. TEVA PHARMACEUTICAL RECENT ACTIVITIES
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.4. EXCEPTIONS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. PIPELINE ANALYSIS
2.3. ANALYST INSIGHT
2.3.1. KEY FINDINGS & CURRENT MARKET TRENDS
2.3.2. RECOMMENDATION
2.3.3. CONCLUSION
2.4. REGULATION
2.4.1. UNITED STATES
2.4.2. EUROPEAN UNION
2.4.3. CHINA
2.4.4. INDIA
2.4.5. REST OF THE WORLD
2.5. PIPELINE ANALYSIS
2.5.1. KEYTRUDA MK-3475 NON-SMALL CELL LUNG CANCER DRUG
2.5.2. ATEZOLIZUMAB (ANTI-PDL1, RG7446, MPDL3280A) ROCHE
2.5.3. RG6016 (ROCHE)
2.5.4. TRASTUZUMAB EMTANSINE (T–DM1)
2.5.5. RG7604 PIK3CA
2.5.6. ALECTINIB (RG7853)
2.5.7. OTHERS
2.6. NEWLY APPROVED DRUGS
2.6.1. ALECENSA (ALECTINIB), ROCHE
2.6.2. KEYTRUDA (PEMBROLIZUMAB), MERCK
2.6.3. OPDIVO (NIVOLUMAB), BRISTOL-MYERS SQUIBB
2.6.4. PORTRAZZA (NECITUMUMAB), ELI LILLY
2.6.5. TAGRISSO (OSIMERTINIB), ASTRAZENECA
2.6.6. ABITREXATE (METHOTREXATE)
2.6.7. AVASTIN (BEVACIZUMAB)
2.6.8. DOCETAXEL
2.6.9. FOLEX (METHOTREXATE)
2.6.10. OTHERS
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. RISE IN INCIDENCE & PREVALENCE RATE OF CANCER DISEASES
3.1.2. RISE IN INVESTMENT AND GRANTS FROM GOVERNMENT AND PRIVATE PLAYERS
3.1.3. RISE IN DIAGNOSTIC CENTERS ACROSS THE GLOBE
3.1.4. GROWTH IN PHARMACEUTICAL MARKET OF LUNG CANCER
3.1.5. RESEARCH & DEVELOPMENT IN LUNG CANCER MARKET
3.1.6. ADOPTION OF INNOVATIVE LUNG SURGERY
3.1.7. FDA CLEARANCE TO LUNG CANCER DRUGS
3.1.8. RISE IN ADOPTION OF PERSONALIZED MEDICINES
3.1.9. RISING MORTALITY RATE DUE TO LUNG CANCER
3.2. RESTRAINT
3.2.1. HIGH COST OF GLOBAL LUNG CANCER DRUGS AND SURGERIES
3.2.2. REIMBURSEMENT POLICIES MAY AFFECT THE GROWTH OF THE MARKET
3.3. OPPORTUNITY
3.3.1. UNTAPPED APAC REGION HAVE HUGE OPPORTUNITY FOR GLOBAL LUNG CANCER MARKET
3.3.2. SUCCESSFUL CLINICAL TRIALS AND FDA APPROVALS
MARKET SEGMENTATION
4.1. LUNG CANCER DRUGS MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
4.1.1. PLATINOL
4.1.2. TAXOL
4.1.3. GEMZAR
4.1.4. ALIMTA
4.1.5. IRESSA
4.1.6. HYCAMTIN
4.1.7. GILOTRIF
4.1.8. TAXOTERE
4.1.9. XALKORI
4.1.10. NAVELBINE
4.1.11. AVASTIN
4.1.12. TARCEVA
4.1.13. OTHERS
COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UK
6.2.2. GERMANY
6.2.3. SPAIN
6.2.4. FRANCE
6.2.5. ITALY
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. REST OF ASIA PACIFIC
6.4. REST OF THE WORLD
COMPANY PROFILES
7.1. ABBVIE
7.1.1. INTRODUCTION
7.1.2. ABBVIE PRODUCT PORTFOLIO
7.1.3. ABBVIE RECENT ACTIVITIES
7.2. AGENNIX
7.2.1. INTRODUCTION
7.2.2. AGENNIX PRODUCT PORTFOLIO
7.2.3. AGENNIX RECENT ACTIVITIES
7.3. AMGEN
7.3.1. INTRODUCTION
7.3.2. AMGEN PRODUCT PORTFOLIO
7.3.3. AMGEN RECENT ACTIVITIES
7.4. ASTRAZENECA
7.4.1. INTRODUCTION
7.4.2. ASTRAZENECA PRODUCT PORTFOLIO
7.4.3. ASTRAZENECA RECENT ACTIVITIES
7.5. BOEHRINGER INGELHEIM
7.5.1. INTRODUCTION
7.5.2. BOEHRINGER INGELHEIM PRODUCT PORTFOLIO
7.5.3. BOEHRINGER INGELHEIM RECENT ACTIVITIES
7.6. CELGENE
7.6.1. INTRODUCTION
7.6.2. CELGENE PRODUCT PORTFOLIO
7.6.3. CELGENE RECENT ACTIVITIES
7.7. CELLDEX
7.7.1. INTRODUCTION
7.7.2. CELLDEX PRODUCT PORTFOLIO
7.7.3. CELLDEX RECENT ACTIVITIES
7.8. EISAI
7.8.1. INTRODUCTION
7.8.2. EISAI PRODUCT PORTFOLIO
7.8.3. EISAI RECENT ACTIVITIES
7.9. ELI LILLY
7.9.1. INTRODUCTION
7.9.2. ELI LILLY PRODUCT PORTFOLIO
7.9.3. ELI LILLY RECENT ACTIVITIES
7.10. F. HOFFMANN-LA ROCHE
7.10.1. INTRODUCTION
7.10.2. F. HOFFMANN-LA ROCHE PRODUCT PORTFOLIO
7.10.3. F. HOFFMANN-LA ROCHE RECENT ACTIVITIES
7.11. GLAXOSMITHKLINE
7.11.1. INTRODUCTION
7.11.2. GLAXOSMITHKLINE PRODUCT PORTFOLIO
7.11.3. GLAXOSMITHKLINE RECENT ACTIVITIES
7.12. HELSINN
7.12.1. INTRODUCTION
7.12.2. HELSINN PRODUCT PORTFOLIO
7.12.3. HELSINN RECENT ACTIVITIES
7.13. IMCLONE
7.13.1. INTRODUCTION
7.13.2. IMCLONE PRODUCT PORTFOLIO
7.13.3. IMCLONE RECENT ACTIVITIES
7.14. MERCK SERONO
7.14.1. INTRODUCTION
7.14.2. MERCK SERONO PRODUCT PORTFOLIO
7.14.3. MERCK SERONO RECENT ACTIVITIES
7.15. NOVARTIS
7.15.1. INTRODUCTION
7.15.2. NOVARTIS PRODUCT PORTFOLIO
7.15.3. NOVARTIS RECENT ACTIVITIES
7.16. ONCOGENEX
7.16.1. INTRODUCTION
7.16.2. ONCOGENEX PRODUCT PORTFOLIO
7.16.3. ONCOGENEX RECENT ACTIVITIES
7.17. OSI PHARMACEUTICALS
7.17.1. INTRODUCTION
7.17.2. OSI PHARMACEUTICALS PRODUCT PORTFOLIO
7.17.3. OSI PHARMACEUTICALS RECENT ACTIVITIES
7.18. PEREGRINE
7.18.1. INTRODUCTION
7.18.2. PEREGRINE PRODUCT PORTFOLIO
7.18.3. PEREGRINE RECENT ACTIVITIES
7.19. PFIZER, INC.
7.19.1. INTRODUCTION
7.19.2. PFIZER, INC. PRODUCT PORTFOLIO
7.19.3. PFIZER, INC. RECENT ACTIVITIES
7.20. PIERRE FABRE
7.20.1. INTRODUCTION
7.20.2. PIERRE FABRE PRODUCT PORTFOLIO
7.20.3. PIERRE FABRE RECENT ACTIVITIES
7.21. QIAGEN
7.21.1. INTRODUCTION
7.21.2. QIAGEN PRODUCT PORTFOLIO
7.21.3. QIAGEN RECENT ACTIVITIES
7.22. ROCHE
7.22.1. INTRODUCTION
7.22.2. ROCHE PRODUCT PORTFOLIO
7.22.3. ROCHE RECENT ACTIVITIES
7.23. SANOFI
7.23.1. INTRODUCTION
7.23.2. SANOFI PRODUCT PORTFOLIO
7.23.3. SANOFI RECENT ACTIVITIES
7.24. SYNTA
7.24.1. INTRODUCTION
7.24.2. SYNTA PRODUCT PORTFOLIO
7.24.3. SYNTA RECENT ACTIVITIES
7.25. TELIK
7.25.1. INTRODUCTION
7.25.2. TELIK PRODUCT PORTFOLIO
7.25.3. TELIK RECENT ACTIVITIES
7.26. TEVA PHARMACEUTICAL
7.26.1. INTRODUCTION
7.26.2. TEVA PHARMACEUTICAL PRODUCT PORTFOLIO
7.26.3. TEVA PHARMACEUTICAL RECENT ACTIVITIES
LIST OF TABLES
Table # 1 GLOBAL LUNG CANCER DRUGS MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 2 GLOBAL PLATINOL MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 3 GLOBAL TAXOL MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 4 GLOBAL GEMZAR MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 5 GLOBAL ALIMTA MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 6 GLOBAL IRESSA MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 7 GLOBAL HYCAMTIN MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 8 GLOBAL GILOTRIF MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 9 GLOBAL TAXOTERE MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 10 GLOBAL XALKORI MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 11 GLOBAL NAVELBINE MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 12 GLOBAL AVASTIN MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 13 GLOBAL TARCEVA MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 14 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 15 ABBVIE PRODUCT PORTFOLIO
Table # 16 ABBVIE RECENT ACTIVITIES
Table # 17 AGENNIX PRODUCT PORTFOLIO
Table # 18 AGENNIX RECENT ACTIVITIES
Table # 19 AMGEN PRODUCT PORTFOLIO
Table # 20 AMGEN RECENT ACTIVITIES
Table # 21 ASTRAZENECA PRODUCT PORTFOLIO
Table # 22 ASTRAZENECA RECENT ACTIVITIES
Table # 23 BOEHRINGER INGELHEIM PRODUCT PORTFOLIO
Table # 24 BOEHRINGER INGELHEIM RECENT ACTIVITIES
Table # 25 CELGENE PRODUCT PORTFOLIO
Table # 26 CELGENE RECENT ACTIVITIES
Table # 27 CELLDEX PRODUCT PORTFOLIO
Table # 28 CELLDEX RECENT ACTIVITIES
Table # 29 EISAI PRODUCT PORTFOLIO
Table # 30 EISAI RECENT ACTIVITIES
Table # 31 EISAIELI LILLY PRODUCT PORTFOLIO
Table # 32 EISAIELI LILLY RECENT ACTIVITIES
Table # 33 F. HOFFMANN-LA ROCHE PRODUCT PORTFOLIO
Table # 34 F. HOFFMANN-LA ROCHE RECENT ACTIVITIES
Table # 35 GLAXOSMITHKLINE PRODUCT PORTFOLIO
Table # 36 GLAXOSMITHKLINE RECENT ACTIVITIES
Table # 37 HELSINN PRODUCT PORTFOLIO
Table # 38 HELSINN RECENT ACTIVITIES
Table # 39 IMCLONE PRODUCT PORTFOLIO
Table # 40 IMCLONE RECENT ACTIVITIES
Table # 41 MERCK SERONO PRODUCT PORTFOLIO
Table # 42 MERCK SERONO RECENT ACTIVITIES
Table # 43 NOVARTIS PRODUCT PORTFOLIO
Table # 44 NOVARTIS RECENT ACTIVITIES
Table # 45 ONCOGENEX PRODUCT PORTFOLIO
Table # 46 ONCOGENEX RECENT ACTIVITIES
Table # 47 OSI PHARMACEUTICALS PRODUCT PORTFOLIO
Table # 48 OSI PHARMACEUTICALS RECENT ACTIVITIES
Table # 49 PEREGRINE PRODUCT PORTFOLIO
Table # 50 PEREGRINE RECENT ACTIVITIES
Table # 51 PFIZER, INC. PRODUCT PORTFOLIO
Table # 52 PFIZER, INC. RECENT ACTIVITIES
Table # 53 PIERRE FABRE PRODUCT PORTFOLIO
Table # 54 PIERRE FABRE RECENT ACTIVITIES
Table # 55 QIAGEN PRODUCT PORTFOLIO
Table # 56 QIAGEN RECENT ACTIVITIES
Table # 57 ROCHE PRODUCT PORTFOLIO
Table # 58 ROCHE RECENT ACTIVITIES
Table # 59 SANOFI PRODUCT PORTFOLIO
Table # 60 SANOFI RECENT ACTIVITIES
Table # 61 SYNTA PRODUCT PORTFOLIO
Table # 62 SYNTA RECENT ACTIVITIES
Table # 63 TELIK PRODUCT PORTFOLIO
Table # 64 TELIK RECENT ACTIVITIES
Table # 65 TEVA PHARMACEUTICAL PRODUCT PORTFOLIO
Table # 66 TEVA PHARMACEUTICAL RECENT ACTIVITIES
Table # 1 GLOBAL LUNG CANCER DRUGS MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 2 GLOBAL PLATINOL MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 3 GLOBAL TAXOL MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 4 GLOBAL GEMZAR MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 5 GLOBAL ALIMTA MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 6 GLOBAL IRESSA MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 7 GLOBAL HYCAMTIN MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 8 GLOBAL GILOTRIF MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 9 GLOBAL TAXOTERE MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 10 GLOBAL XALKORI MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 11 GLOBAL NAVELBINE MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 12 GLOBAL AVASTIN MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 13 GLOBAL TARCEVA MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 14 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2015-2021, ($ MILLIONS)
Table # 15 ABBVIE PRODUCT PORTFOLIO
Table # 16 ABBVIE RECENT ACTIVITIES
Table # 17 AGENNIX PRODUCT PORTFOLIO
Table # 18 AGENNIX RECENT ACTIVITIES
Table # 19 AMGEN PRODUCT PORTFOLIO
Table # 20 AMGEN RECENT ACTIVITIES
Table # 21 ASTRAZENECA PRODUCT PORTFOLIO
Table # 22 ASTRAZENECA RECENT ACTIVITIES
Table # 23 BOEHRINGER INGELHEIM PRODUCT PORTFOLIO
Table # 24 BOEHRINGER INGELHEIM RECENT ACTIVITIES
Table # 25 CELGENE PRODUCT PORTFOLIO
Table # 26 CELGENE RECENT ACTIVITIES
Table # 27 CELLDEX PRODUCT PORTFOLIO
Table # 28 CELLDEX RECENT ACTIVITIES
Table # 29 EISAI PRODUCT PORTFOLIO
Table # 30 EISAI RECENT ACTIVITIES
Table # 31 EISAIELI LILLY PRODUCT PORTFOLIO
Table # 32 EISAIELI LILLY RECENT ACTIVITIES
Table # 33 F. HOFFMANN-LA ROCHE PRODUCT PORTFOLIO
Table # 34 F. HOFFMANN-LA ROCHE RECENT ACTIVITIES
Table # 35 GLAXOSMITHKLINE PRODUCT PORTFOLIO
Table # 36 GLAXOSMITHKLINE RECENT ACTIVITIES
Table # 37 HELSINN PRODUCT PORTFOLIO
Table # 38 HELSINN RECENT ACTIVITIES
Table # 39 IMCLONE PRODUCT PORTFOLIO
Table # 40 IMCLONE RECENT ACTIVITIES
Table # 41 MERCK SERONO PRODUCT PORTFOLIO
Table # 42 MERCK SERONO RECENT ACTIVITIES
Table # 43 NOVARTIS PRODUCT PORTFOLIO
Table # 44 NOVARTIS RECENT ACTIVITIES
Table # 45 ONCOGENEX PRODUCT PORTFOLIO
Table # 46 ONCOGENEX RECENT ACTIVITIES
Table # 47 OSI PHARMACEUTICALS PRODUCT PORTFOLIO
Table # 48 OSI PHARMACEUTICALS RECENT ACTIVITIES
Table # 49 PEREGRINE PRODUCT PORTFOLIO
Table # 50 PEREGRINE RECENT ACTIVITIES
Table # 51 PFIZER, INC. PRODUCT PORTFOLIO
Table # 52 PFIZER, INC. RECENT ACTIVITIES
Table # 53 PIERRE FABRE PRODUCT PORTFOLIO
Table # 54 PIERRE FABRE RECENT ACTIVITIES
Table # 55 QIAGEN PRODUCT PORTFOLIO
Table # 56 QIAGEN RECENT ACTIVITIES
Table # 57 ROCHE PRODUCT PORTFOLIO
Table # 58 ROCHE RECENT ACTIVITIES
Table # 59 SANOFI PRODUCT PORTFOLIO
Table # 60 SANOFI RECENT ACTIVITIES
Table # 61 SYNTA PRODUCT PORTFOLIO
Table # 62 SYNTA RECENT ACTIVITIES
Table # 63 TELIK PRODUCT PORTFOLIO
Table # 64 TELIK RECENT ACTIVITIES
Table # 65 TEVA PHARMACEUTICAL PRODUCT PORTFOLIO
Table # 66 TEVA PHARMACEUTICAL RECENT ACTIVITIES
LIST OF FIGURES
Figure # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 4 REST OF NORTH AMERICA MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 5 EUROPE MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 6 UK MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure #7 GERMANY MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure #8 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 9 FRANCE MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 10 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 11 ITALY MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 12 REST OF EUROPE MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 13 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 14 INDIA MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 15 CHINA MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 16 JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 17 ROPAC MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 18 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 4 REST OF NORTH AMERICA MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 5 EUROPE MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 6 UK MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure #7 GERMANY MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure #8 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 9 FRANCE MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 10 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 11 ITALY MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 12 REST OF EUROPE MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 13 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 14 INDIA MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 15 CHINA MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 16 JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 17 ROPAC MARKET RESEARCH AND ANALYSIS, 2015-2021
Figure # 18 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2015-2021
